Vascular risk factors and diabetic neuropathy
- PMID: 15673800
- DOI: 10.1056/NEJMoa032782
Vascular risk factors and diabetic neuropathy
Abstract
Background: Other than glycemic control, there are no treatments for diabetic neuropathy. Thus, identifying potentially modifiable risk factors for neuropathy is crucial. We studied risk factors for the development of distal symmetric neuropathy in 1172 patients with type 1 diabetes mellitus from 31 centers participating in the European Diabetes (EURODIAB) Prospective Complications Study.
Methods: Neuropathy was assessed at baseline (1989 to 1991) and at follow-up (1997 to 1999), with a mean (+/-SD) follow-up of 7.3+/-0.6 years. A standardized protocol included clinical evaluation, quantitative sensory testing, and autonomic-function tests. Serum lipids and lipoproteins, glycosylated hemoglobin, and the urinary albumin excretion rate were measured in a central laboratory.
Results: At follow-up, neuropathy had developed in 276 of 1172 patients without neuropathy at baseline (23.5 percent). The cumulative incidence of neuropathy was related to the glycosylated hemoglobin value and the duration of diabetes. After adjustment for these factors, we found that higher levels of total and low-density lipoprotein cholesterol and triglycerides, a higher body-mass index, higher von Willebrand factor levels and urinary albumin excretion rate, hypertension, and smoking were all significantly associated with the cumulative incidence of neuropathy. After adjustment for other risk factors and diabetic complications, we found that duration of diabetes, current glycosylated hemoglobin value, change in glycosylated hemoglobin value during the follow-up period, body-mass index, and smoking remained independently associated with the incidence of neuropathy. Cardiovascular disease at baseline was associated with double the risk of neuropathy, independent of cardiovascular risk factors.
Conclusions: This prospective study indicates that, apart from glycemic control, the incidence of neuropathy is associated with potentially modifiable cardiovascular risk factors, including a raised triglyceride level, body-mass index, smoking, and hypertension.
Copyright 2005 Massachusetts Medical Society.
Comment in
-
Early vascular risk factor modification in type 1 diabetes.N Engl J Med. 2005 Jan 27;352(4):408-9. doi: 10.1056/NEJMe048340. N Engl J Med. 2005. PMID: 15673807 No abstract available.
-
Vascular risk factors and diabetic neuropathy.N Engl J Med. 2005 May 5;352(18):1925-7; author reply 1925-7. doi: 10.1056/NEJM200505053521817. N Engl J Med. 2005. PMID: 15872210 No abstract available.
-
Vascular risk factors and diabetic neuropathy.N Engl J Med. 2005 May 5;352(18):1925-7; author reply 1925-7. N Engl J Med. 2005. PMID: 15877320 No abstract available.
-
Vascular risk factors and diabetic neuropathy.N Engl J Med. 2005 May 5;352(18):1925-7; author reply 1925-7. N Engl J Med. 2005. PMID: 15877321 No abstract available.
Similar articles
-
Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study.Diabetologia. 1997 Jun;40(6):698-705. doi: 10.1007/s001250050736. Diabetologia. 1997. PMID: 9222650
-
Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients.Diab Vasc Dis Res. 2018 Sep;15(5):424-432. doi: 10.1177/1479164118780808. Epub 2018 Jun 18. Diab Vasc Dis Res. 2018. PMID: 29911415
-
Risk factors for progression of distal symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research Group.Am J Epidemiol. 1999 Dec 1;150(11):1142-51. doi: 10.1093/oxfordjournals.aje.a009941. Am J Epidemiol. 1999. PMID: 10588075
-
Modifiable vascular risk factors are associated with diabetic neuropathy in type 1 diabetes.Postgrad Med. 2005 Apr;117(4):7. doi: 10.3810/pgm.2005.04.1811. Postgrad Med. 2005. PMID: 15842127 Review. No abstract available.
-
The Eurodiab study: what has this taught us about diabetic peripheral neuropathy?Curr Diab Rep. 2009 Dec;9(6):432-4. doi: 10.1007/s11892-009-0070-1. Curr Diab Rep. 2009. PMID: 19954687 Review.
Cited by
-
Association of platelet count and plateletcrit with nerve conduction function and peripheral neuropathy in patients with type 2 diabetes mellitus.J Diabetes Investig. 2021 Oct;12(10):1835-1844. doi: 10.1111/jdi.13535. Epub 2021 Mar 23. J Diabetes Investig. 2021. PMID: 33650778 Free PMC article.
-
Genetic Variants Influence the Development of Diabetic Neuropathy.Int J Mol Sci. 2024 Jun 11;25(12):6429. doi: 10.3390/ijms25126429. Int J Mol Sci. 2024. PMID: 38928135 Free PMC article. Review.
-
Prediction of protective sensory loss, neuropathy and foot ulceration in type 2 diabetes.BMJ Open Diabetes Res Care. 2016 May 5;4(1):e000163. doi: 10.1136/bmjdrc-2015-000163. eCollection 2016. BMJ Open Diabetes Res Care. 2016. PMID: 27239314 Free PMC article.
-
Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats.Pharmaceuticals (Basel). 2024 Jun 14;17(6):783. doi: 10.3390/ph17060783. Pharmaceuticals (Basel). 2024. PMID: 38931450 Free PMC article.
-
Advances in the laboratory evaluation of peripheral neuropathies.Curr Neurol Neurosci Rep. 2012 Feb;12(1):84-91. doi: 10.1007/s11910-011-0239-2. Curr Neurol Neurosci Rep. 2012. PMID: 22147264 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical